The ACTIV-6 trial reports that people who took the drug for three days may have spent slightly less time feeling unwell with SARS-CoV-2, but fails to find differences in disease progression between the treatment and placebo groups.
The Swiss Federal Institute of Technology Lausanne evolutionary neurobiologist is using Drosophila to investigate how organisms adapt to novel environments.
Chris McGinnis will describe the advantages and applications of MULTI-seq using lipid-modified oligonucleotides, while Jennifer Silverman will discuss using the MULTI-seq Lipid-Modified Oligos kit in single-cell analysis workflows.
Thanks for reading! I'm Christie, and I curate and edit this newsletter. My inbox is always open, so if you have thoughts or ideas about this newsletter or tips for our news team, I'd love to hear from you.
Want More? We also offer curated newsletters that focus in on research areas, including Microbiology and Life.
Advertisement
Follow The Scientist
Never miss an email from The Scientist. Click hereto add The Scientist to your safe-sender list.
The Scientist,1000 N West Street, Suite 1200, Wilmington, Delaware, United States, 19801 Toll-Free: (888) 781-0328 | Phone: (705) 528-6888 Email: privacy@the-scientist.com